biolitec AG continues strong revenue and profit growth in the first half of the year - EBIT growth of 23 % up to Euro 3.0 million - BPH laser were placed in the market as planned

--------------------------------------------------------------------------------
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
the content of this announcement.
--------------------------------------------------------------------------------

Jena (euro adhoc) - Jena, February 29th 2008 - biolitec AG, Jena, listed in the
Prime Standard of the Frankfurt stock exchange (ISIN DE0005213409) managed to
in-crease consolidated revenues by 12 % to Euro 19.1 million during the first
six months ending December 31, 2007 (previous year: Euro 17.1 million). The
gross profit amounted Euro 13.0 million (previous year: Euro 11.7 mil-lion). The
earnings before interest and taxes (EBIT) increased up to Euro 3.0 million (plus
23 %).

Thanks to the sales increases especially in BPH and aesthetic treatment systems
of biolitec AG, for example ELVeS™, the net income amounted Euro 2.2 million
(previous year: Euro 1.9 million). With new LIFE™ laser therapy using the EVOLVE
™ urology laser, biolitec AG establishes an un-complicated and effective
procedure for a new and innovative medical care for patients with benign
prostate hyperplasia in Germany and the United States. LIFE™ laser therapy is
already available in more than 20 treatment centres in Germany. Inpatient
treatment costs are reimbursed by statutory health insurance since 2008. With
Endo Laser Vein System - ELVeS™ bio-litec also has created a new worldwide
standard for the treatment of venous insufficiency.

Second quarter revenue increase was modest (from Euro 9.7 million up to Euro 9.8
million) due to a shifting effect to direct sales from distribu-tors/marketing
partners. Dr. Wolfgang Neuberger, CEO of biolitec AG comments: "We expect that
the attractive reimbursement rates for BPH treatments using laser adopted in
January 2008 will speed up the adoption of the new therapy in Germany in
particular. While laser placements pro-ceeded at a good rate in the US, closings
were behind expectations. We expect to reach our BPH market share goal of 40 %
in the US within 12 to 24 months".

With Euro 3.2 million (17 % of sales) in the first six months of the business
year, R&D expenditures of biolitec remain at a high level, ensuring the groups
long term growth and profitability. The strongest increases with 7 %
respectively 23 % were achieved in biolitec´s traditional fields´ fibers/probes
and lasers. North American revenues increased by 23 % in the first six months,
accounting for 51 % of total sales.

For the course of the year biolitec expects an ongoing positive business
development. The current growth is mainly driven by the strong demand for the
company´s BPH treatment, the new ELVeS™ PainLess vein therapy and aesthetic
therapies in general. The photodynamic therapy using the cancer drug Foscan®
shows steadily to be a successful development. An important milestone for
Foscan® was the approval of low-dose Foscan® vials. In December 2007 the cancer
drug has also received approval of the regulatory authority in Argentina. "With
this approval we can now work to-gether with our local distributor to start the
sales and marketing activities in Argentina", added Dr. Neuberger.

About biolitec
biolitec is the only supplier for photodynamic therapy worldwide that offers all
rele-vant core competencies - photosensitizers, lasers and optical fibers.
Besides minimal invasive laser treatments and the oncology business biolitec has
success-fully developed competencies in the field of aesthetics. biolitec is
listed in the Prime Standard under ISIN DE0005213409. For more information:
www.biolitec.com.

Further inquiry note:
Press contact
Jörn Gleisner
Phone : +49 (0) 69 / 959083-20
Fax : +49 (0) 69 / 959083-99
E-mail: [email protected]

end of announcement euro adhoc
--------------------------------------------------------------------------------

emitter: biolitec AG
Winzerlaer Straße 2a
D-07745 Jena
phone: +49 (0)3641 5 08-5 50
FAX: +49 (0)3641 5 08-5 99
mail: [email protected]
WWW: www.biolitec.de
sector: Pharmaceuticals
ISIN: DE0005213409
indexes: CDAX, Prime All Share, Technologie All Share
stockmarkets: regulated dealing/prime standard: Börse Frankfurt, free trade:
Börse Berlin, Börse Hamburg, Börse Stuttgart, Börse Düsseldorf,
Börse München
language: English

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | CNE

print